Nasdaq-Listed Enlivex Therapeutics Proposes $400-800M Private Placement Deal Involving Cryptocurrency Tokens

Jul 31, 2026

Enlivex Therapeutics has proposed a private placement deal of up to $800 million with a single institutional investor, structured as an initial $400 million placement with a $400 million discretionary put option. The deal allows funding in RAIN tokens at a premium price of $6.00 per share. The proposal, which allocates up to 95% of proceeds to token acquisitions and only 5% to clinical drug development, could dilute existing shares by 951%. Following the announcement, Enlivex stock plummeted 47.42% on July 28, 2026.

$400M private placement structure

▪Enlivex Therapeutics entered into a securities purchase agreement with a single institutional investor for a private placement of approximately $400,000,000 of ordinary shares or equivalents.
▪The securities purchase agreement grants Enlivex Therapeutics a discretionary right, exercisable for 36 months post-closing, to require the investor to purchase up to an additional $400,000,000 of securities.

Cryptocurrency token funding mechanism

▪Shares funded in U.S. dollars, USDT, or USD Coin are priced at $5.00, representing a 17.4% premium to the July 27, 2026 closing price.
▪Shares funded in RAIN tokens are priced at $6.00, representing a 40.8% premium to the July 27, 2026 closing price.
▪The institutional investor has currently elected to fund the purchase in RAIN tokens, though this election may be changed before closing.

Shareholder approval requirements

▪If approved, the proposed transaction could increase the outstanding share count of Enlivex Therapeutics by as much as 951% from current levels.
▪Enlivex Therapeutics intends to hold a shareholder meeting within 60 days of the announcement to seek approval for the transaction.
▪Closing of the transaction is subject to shareholder approval under Nasdaq Listing Rules 5635(a), 5635(b), and Section 274 of the Israeli Companies Law.

Treasury strategy for Rain protocol

▪The proposed transaction structure earmarks the majority of proceeds for RAIN token acquisitions, with up to 5% allocated to drug development.
▪Enlivex Therapeutics plans to use the net proceeds to advance its treasury strategy built around the Rain protocol, a decentralized prediction markets infrastructure on Arbitrum.

Clinical program funding plans

▪Enlivex Therapeutics operates a dual strategy combining the development of longevity therapeutics with exposure to the emerging prediction markets ecosystem.
▪Enlivex Therapeutics plans to use a portion of the proceeds to continue advancing Allocetra, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, primarily age-related osteoarthritis.

Stock volatility following announcement

▪The stock of Enlivex Therapeutics experienced high volatility during the July 28, 2026 session, tracking a peak move of +87.6% and a trough of -54.3%.
▪On July 28, 2026, shares of Enlivex Therapeutics declined 47.42% in the session following the announcement, with trading volume reaching 49.9 times the daily average.